PMID- 33431345
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20240402
IS  - 2451-9030 (Electronic)
IS  - 2451-9022 (Print)
IS  - 2451-9022 (Linking)
VI  - 6
IP  - 2
DP  - 2021 Feb
TI  - Forecasting Remission From the Psychosis Risk Syndrome With Mismatch Negativity 
      and P300: Potentials and Pitfalls.
PG  - 178-187
LID - S2451-9022(20)30314-1 [pii]
LID - 10.1016/j.bpsc.2020.10.010 [doi]
AB  - Clinical outcomes vary for individuals at clinical high risk (CHR) for psychosis, 
      ranging from conversion to a psychotic disorder to full remission from the risk 
      syndrome. Given that most CHR individuals do not convert to psychosis, recent 
      research efforts have turned toward identifying specific predictors of CHR 
      remission, a task that is conceptually and empirically dissociable from the 
      identification of predictors of conversion to psychosis, and one that may reveal 
      specific biological characteristics that confer resilience to psychosis and 
      provide further insights into the mechanisms associated with the pathogenesis of 
      schizophrenia and those underlying a transient CHR syndrome. Such biomarkers may 
      ultimately facilitate the development of novel early interventions and support 
      the optimization of individualized care. In this review, we focus on two 
      event-related brain potential measures, mismatch negativity and P300, that have 
      attracted interest as predictors of future psychosis among CHR individuals. We 
      describe several recent studies examining whether mismatch negativity and P300 
      predict subsequent CHR remission and suggest that intact mismatch negativity and 
      P300 may reflect the integrity of specific neurocognitive processes that confer 
      resilience against the persistence of the CHR syndrome and its associated risk 
      for future transition to psychosis. We also highlight several major 
      methodological concerns associated with these studies that apply to the broader 
      literature examining predictors of CHR remission. Among them is the concern that 
      studies that predict dichotomous remission versus nonremission and/or dichotomous 
      conversion versus nonconversion outcomes potentially confound remission and 
      conversion effects, a phenomenon we demonstrate with a data simulation.
CI  - Published by Elsevier Inc.
FAU - Hamilton, Holly K
AU  - Hamilton HK
AD  - San Francisco VA Health Care System, University of California San Francisco, San 
      Francisco, California; Department of Psychiatry and Behavioral Sciences, 
      University of California San Francisco, San Francisco, California. Electronic 
      address: holly.hamilton@ucsf.edu.
FAU - Roach, Brian J
AU  - Roach BJ
AD  - San Francisco VA Health Care System, University of California San Francisco, San 
      Francisco, California; Northern California Institute for Research and Education, 
      San Francisco, California.
FAU - Mathalon, Daniel H
AU  - Mathalon DH
AD  - San Francisco VA Health Care System, University of California San Francisco, San 
      Francisco, California; Department of Psychiatry and Behavioral Sciences, 
      University of California San Francisco, San Francisco, California. Electronic 
      address: daniel.mathalon@ucsf.edu.
LA  - eng
GR  - IK2 CX001878/CX/CSRD VA/United States
GR  - R01 MH076989/MH/NIMH NIH HHS/United States
GR  - U01 MH076989/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20201024
PL  - United States
TA  - Biol Psychiatry Cogn Neurosci Neuroimaging
JT  - Biological psychiatry. Cognitive neuroscience and neuroimaging
JID - 101671285
SB  - IM
MH  - Brain
MH  - Evoked Potentials
MH  - Humans
MH  - *Psychotic Disorders/diagnosis
MH  - Remission Induction
MH  - *Schizophrenia
PMC - PMC8128162
MID - NIHMS1661679
OTO - NOTNLM
OT  - Clinical high risk for psychosis
OT  - Electroencephalography
OT  - Mismatch negativity
OT  - P300
OT  - Remission
OT  - Schizophrenia
COIS- Disclosures Dr. Hamilton and Mr. Roach report no biomedical financial interests 
      or potential conflicts of interest. Dr. Mathalon is a consultant for Boehringer 
      Ingelheim and Cadent Therapeutics.
EDAT- 2021/01/13 06:00
MHDA- 2021/06/04 06:00
PMCR- 2022/02/01
CRDT- 2021/01/12 05:49
PHST- 2020/08/15 00:00 [received]
PHST- 2020/10/19 00:00 [revised]
PHST- 2020/10/20 00:00 [accepted]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2021/01/12 05:49 [entrez]
PHST- 2022/02/01 00:00 [pmc-release]
AID - S2451-9022(20)30314-1 [pii]
AID - 10.1016/j.bpsc.2020.10.010 [doi]
PST - ppublish
SO  - Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Feb;6(2):178-187. doi: 
      10.1016/j.bpsc.2020.10.010. Epub 2020 Oct 24.